You are here

  • Home
  • Archive
  • Volume 22, Issue 5
  • In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids

Article Text

Article menu
Download PDFPDF
Commentary
General medicine
In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids

https://doi.org/10.1136/ebmed-2017-110726

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests MC and PR are consultants and/or members of the Speaker Bureau at AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici and Novartis.

    • Provenance and peer review Commissioned; internally peer reviewed.